Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Rival BTK degraders face off in CLL patients naive to BTK inhibition.
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
What could be the four HengRui assets picked up by Bristol?
